Dr. Herbst on Nivolumab for NSCLC

Roy S. Herbst, MD, PhD
Published: Wednesday, Apr 22, 2015



Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the impact of the FDA approval of nivolumab for the treatment of squamous non-small cell lung cancer.

Now that nivolumab has been approved and studies have shown it improves survival, the focus should shift to how to integrate it with other therapies, says Herbst.

Researchers should investigate how nivolumab combines with chemotherapy, targeted therapies and other immunotherapies. Understanding how nivolumab can best be used will be very important for the future treatment of NSCLC, says Herbst.

<<< View more from the 2015 AACR Annual Meeting



Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the impact of the FDA approval of nivolumab for the treatment of squamous non-small cell lung cancer.

Now that nivolumab has been approved and studies have shown it improves survival, the focus should shift to how to integrate it with other therapies, says Herbst.

Researchers should investigate how nivolumab combines with chemotherapy, targeted therapies and other immunotherapies. Understanding how nivolumab can best be used will be very important for the future treatment of NSCLC, says Herbst.

<<< View more from the 2015 AACR Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x